Helixmith Receives MFDS Approval for NGENSIS Phase 1/2a Clinical Trial Plan
[Asia Economy Reporter Geum Bo-ryeong] Helixmith announced on the 21st that the Phase 1/2a clinical trial plan for the Charcot-Marie-Tooth disease treatment 'Engensis (VM202)' has been approved by the Ministry of Food and Drug Safety.
Hot Picks Today
"Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- "Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- 'Will Demand Finally Decline Due to High Prices?'... "I'll Just Enjoy Nearby Trips" as Japan and China See a Surge
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
Helixmith stated, "The purpose is to evaluate the safety and tolerability of the investigational drug injected into weakened lower limb muscles of Charcot-Marie-Tooth 1A patients," adding, "The clinical trial will be conducted for 12 months after approval by the MFDS at one institution, Samsung Seoul Hospital, with 12 participants."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
